These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9645897)

  • 1. Effect of beta-blocker therapy in patients with coronary artery disease in New York Heart Association classes II and III. The Bezafibrate Infarction Prevention (BIP) Study Group.
    Haim M; Shotan A; Boyko V; Reicher-Reiss H; Benderly M; Goldbourt U; Behar S
    Am J Cardiol; 1998 Jun; 81(12):1455-60. PubMed ID: 9645897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group.
    Jonas M; Reicher-Reiss H; Boyko V; Shotan A; Mandelzweig L; Goldbourt U; Behar S
    Am J Cardiol; 1996 Jun; 77(15):1273-7. PubMed ID: 8677865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative.
    Coiro S; Girerd N; Rossignol P; Ferreira JP; Maggioni A; Pitt B; Tritto I; Ambrosio G; Dickstein K; Zannad F
    Eur J Heart Fail; 2017 Feb; 19(2):271-279. PubMed ID: 27774703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery.
    Zhang H; Yuan X; Zhang H; Chen S; Zhao Y; Hua K; Rao C; Wang W; Sun H; Hu S; Zheng Z
    Circulation; 2015 Jun; 131(25):2194-201. PubMed ID: 25908770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure.
    Bunch TJ; Muhlestein JB; Bair TL; Renlund DG; Lappé DL; Jensen KR; Horne BD; Carter MA; Anderson JL;
    Am J Cardiol; 2005 Apr; 95(7):827-31. PubMed ID: 15781009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: Analysis of the CARDIf Study Cohort.
    Vitale C; Iellamo F; Volterrani M; Lombardi M; Fini M; Banach M; Rosano GM
    Angiology; 2010 Nov; 61(8):763-7. PubMed ID: 20462892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.
    Sorbets E; Steg PG; Young R; Danchin N; Greenlaw N; Ford I; Tendera M; Ferrari R; Merkely B; Parkhomenko A; Reid C; Tardif JC; Fox KM;
    Eur Heart J; 2019 May; 40(18):1399-1407. PubMed ID: 30590529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-blockers for coronary heart disease in chronic kidney disease.
    Chonchol M; Benderly M; Goldbourt U
    Nephrol Dial Transplant; 2008 Jul; 23(7):2274-9. PubMed ID: 18187497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project.
    Chen J; Marciniak TA; Radford MJ; Wang Y; Krumholz HM
    J Am Coll Cardiol; 1999 Nov; 34(5):1388-94. PubMed ID: 10551683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis.
    Tenenbaum A; Motro M; Fisman EZ; Leor J; Boyko V; Mandelzweig L; Behar S
    Cardiology; 2003; 100(4):207-15. PubMed ID: 14713732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between β-Blocker Therapy at Discharge and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Li C; Sun Y; Shen X; Yu T; Li Q; Ruan G; Zhang L; Huang Q; Zhuang H; Huang J; Ni L; Wang L; Jiang J; Wang Y; Wang DW
    J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27852588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor functional status based on the New York Heart Association classification exposes the coronary patient to an elevated risk of ischemic stroke.
    Koren-Morag N; Goldbourt U; Tanne D
    Am Heart J; 2008 Mar; 155(3):515-20. PubMed ID: 18294489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
    Bangalore S; Steg G; Deedwania P; Crowley K; Eagle KA; Goto S; Ohman EM; Cannon CP; Smith SC; Zeymer U; Hoffman EB; Messerli FH; Bhatt DL;
    JAMA; 2012 Oct; 308(13):1340-9. PubMed ID: 23032550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent transient myocardial ischemia despite beta-adrenergic blockade predicts a higher risk of adverse cardiac events in patients with coronary artery disease.
    Madjlessi-Simon T; Mary-Krause M; Fillette F; Lechat P; Jaillon P
    J Am Coll Cardiol; 1996 Jun; 27(7):1586-91. PubMed ID: 8636540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.
    Motivala AA; Parikh V; Roe M; Dai D; Abbott JD; Prasad A; Mukherjee D
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1639-48. PubMed ID: 27539683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease.
    Andersson C; Shilane D; Go AS; Chang TI; Kazi D; Solomon MD; Boothroyd DB; Hlatky MA
    J Am Coll Cardiol; 2014 Jul; 64(3):247-52. PubMed ID: 25034059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.
    Lanfear DE; Jones PG; Marsh S; Cresci S; McLeod HL; Spertus JA
    JAMA; 2005 Sep; 294(12):1526-33. PubMed ID: 16189366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study.
    Andersson C; Mérie C; Jørgensen M; Gislason GH; Torp-Pedersen C; Overgaard C; Køber L; Jensen PF; Hlatky MA
    JAMA Intern Med; 2014 Mar; 174(3):336-44. PubMed ID: 24247428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of β-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction.
    Steinman MA; Zullo AR; Lee Y; Daiello LA; Boscardin WJ; Dore DD; Gan S; Fung K; Lee SJ; Komaiko KD; Mor V
    JAMA Intern Med; 2017 Feb; 177(2):254-262. PubMed ID: 27942713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction.
    Soumerai SB; McLaughlin TJ; Spiegelman D; Hertzmark E; Thibault G; Goldman L
    JAMA; 1997 Jan; 277(2):115-21. PubMed ID: 8990335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.